Evidence map›Paper›PMID 30012179›Full record

Trial reportParasites & vectors2018

Six-month field efficacy and safety of the combined treatment of dogs with Frontline Tri-Act® and NexGard Spectra®.

Jessica M Abbate, Ettore Napoli, Francesca Arfuso, Gabriella Gaglio, Salvatore Giannetto, Lenaig Halos, Frederic Beugnet, Emanuele Brianti

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in Parasites & vectors, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Jessica M AbbateDipartimento di Scienze Veterinarie, Università degli Studi di Messina, Polo Universitario Annunziata, 98168, Messina, Italy.
Ettore NapoliDipartimento di Scienze Veterinarie, Università degli Studi di Messina, Polo Universitario Annunziata, 98168, Messina, Italy.
Francesca ArfusoDipartimento di Scienze Veterinarie, Università degli Studi di Messina, Polo Universitario Annunziata, 98168, Messina, Italy.
Gabriella GaglioDipartimento di Scienze Veterinarie, Università degli Studi di Messina, Polo Universitario Annunziata, 98168, Messina, Italy.
Salvatore GiannettoDipartimento di Scienze Veterinarie, Università degli Studi di Messina, Polo Universitario Annunziata, 98168, Messina, Italy.
Lenaig HalosBoehringer-Ingelheim Animal Health, 29 Av Tony Garnier, Lyon, France.
Frederic BeugnetBoehringer-Ingelheim Animal Health, 29 Av Tony Garnier, Lyon, France.
Emanuele BriantiDipartimento di Scienze Veterinarie, Università degli Studi di Messina, Polo Universitario Annunziata, 98168, Messina, Italy. ebrianti@unime.it.
University of Messina · ITDépartement Santé Animale · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSafety and efficacy of the combined monthly use of spot-on fipronil 6.76% w/v / permethrin 50.48% w/v (Frontline Tri-Act®) and chewable tablets of afoxolaner 1.9% w/w / milbemycin oxime 0.4% w/w (NexGard Spectra®) in dogs was evaluated in a field study over a period of 6 months.

methodsForty-one healthy dogs living in highly endemic area for canine leishmaniosis and other canine vector borne diseases (VBD) were included in the study at the beginning of the Leishmania transmission season. Sixteen dogs were pet dogs living each in a single household; twenty-five dogs were hunting dogs living in three kennels. At inclusion, the dogs were ELISA (rapid test) negative for antibodies to Anaplasma, Borrelia, Ehrlichia, and for antigens of Dirofilaria. The dogs were also negative for blood microfilariae at the Knott's test, and no clinical or haematological abnormalities were observed. Of the included dogs, six hunting, apparently healthy, dogs were ELISA (rapid test) positive to Leishmania, and some were naturally infected by gastrointestinal nematodes (58.5%) and/or infested by fleas (58.5%) and ticks (9.8%). All the included dogs were treated at Days 0, 28, 56, 84, 112 and 140, and followed-up for efficacy until the study end (Day 168).

resultsNo adverse events related to the two products, nor skin reactions, general signs, or changes in the haematological profile, were observed during the study. At Day 14, anthelminthic efficacy was 100% for Toxocara canis, Toxascaris leonina and Capillaria aerophila, while few hunting dogs were still shedding eggs of Trichuris vulpis (1/25 hunting dog) and Ancylostomatidae (9/25 hunting dogs). All pet dogs were nematode free at the end of the study. Hunting dogs were free of roundworms and whipworms. Twenty-four hours after the first treatment, 95.8% of the ectoparasite infested dogs were free from fleas and ticks. Ectoparasites were significantly controlled during the 6-month study period, with 100% efficacy on both fleas and ticks from Day 56 to Day 168. Blood and serum samples collected on Day 168 were tested for vector-borne pathogens using same methods of the inclusion and no new seroconversions or circulating blood microfilariae were observed.

conclusionsConcomitant use of Frontline Tri-Act® and NexGard Spectra® in dogs for six months was well tolerated. The combination was effective in controlling fleas, ticks, gastro-intestinal nematodes, and neither new seroconversion to the tested vector-borne pathogens nor blood microfilariae were detected in treated dogs at the end of the study.

Indexed as

AnimalsDog DiseasesDogsDrug CombinationsFemaleInsecticidesInsect VectorsIsoxazolesMacrolidesMaleNaphthalenesParasitic Diseases, AnimalPermethrinPyrazolesafoxolanerDrug CombinationsfipronilInsecticidesIsoxazolesMacrolidesmoxidectinNaphthalenesPermethrinPyrazolesAfoxolaner/milbemycin oximeCanine vector-borne diseasesEctoparasitesEfficacyFipronil/permethrinNematodesSafety

Identifiers

PMID30012179
PMCPMC6048810
OpenAlexW2884937581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.